{"product_id":"american-society-of-nephrology-kidney-week-glomerular-diseases-update-2025","title":"American Society of Nephrology Kidney Week Glomerular Diseases Update 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: nephrologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis course is consistently one of the most popular early programs, designed to be a “one-stop shop” for updates on glomerular pathology. The 2025 edition focused on the explosion of new therapeutic options, particularly for IgA Nephropathy (IgAN) and Lupus Nephritis, helping clinicians navigate the increasingly crowded landscape of B-cell therapies and complement inhibitors.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWhat You Will Learn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eThe curriculum was designed to update the “mental models” of clinicians regarding disease pathogenesis and treatment. Key learning outcomes included:\u003c\/h3\u003e\n\u003cp\u003eIgA Nephropathy Revolution: How to choose between the multiple new FDA-approved options (e.g., endothelin receptor antagonists vs. B-cell depleters vs. complement inhibitors) based on patient profiles.\u003c\/p\u003e\n\u003cp\u003eLupus Nephritis (LN): Interpreting the 2024 KDIGO Guidelines update, specifically regarding the timing of “add-on” therapies (like voclosporin or belimumab) to standard of care.\u003c\/p\u003e\n\u003cp\u003eThe “Podocytopathy” Reclassification: Moving away from “FSGS” and “MCD” toward a molecular classification based on autoantibodies (e.g., anti-nephrin) and genetic drivers.\u003c\/p\u003e\n\u003cp\u003eAI in Diagnosis: Anticipated uses of Artificial Intelligence to read renal biopsies and predict prognosis in glomerular disease.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEvent Details\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEvent: Glomerular Diseases: 2025 Update (ASN Early Program)\u003c\/p\u003e\n\u003cp\u003eDate: November 5, 2025 (Wednesday)\u003c\/p\u003e\n\u003cp\u003eLocation: Grand Ballroom B, George R. Brown Convention Center, Houston, Texas, USA\u003c\/p\u003e\n\u003cp\u003eChairs: Rupali S. Avasare, MD \u0026amp; John Cijiang He, MD, PhD.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWho Should Attend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eGeneral Nephrologists: Who need to feel confident managing complex glomerulonephritis without immediately referring to a tertiary center.\u003c\/p\u003e\n\u003cp\u003eNephropathologists: Interested in the clinical correlation of the biopsies they read.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWhy Attend (or Watch)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe “CPC” Format: The course is anchored by two major Clinicopathologic Conferences (CPCs)—one on Nephritic Syndrome and one on Nephrotic Syndrome. These sessions feature a “case detective” format where experts debate the diagnosis before the biopsy is revealed, offering invaluable insight into clinical reasoning.\u003c\/p\u003e\n\u003cp\u003eGenetics Integration: A major theme for 2025 was “When to Order Genetics,” moving beyond Alport Syndrome to testing for APOL1 and collagen 4 mutations in adults with “presumed” hypertensive sclerosis.\u003c\/p\u003e\n\u003cp\u003eFaculty Access: Speakers included leaders in the field like Dr. Richard Lafayette (IgAN) and Dr. Duvuru Geetha (Vasculitis), who are often the principal investigators on the trials being discussed.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eThe agenda featured specific high-yield modules:\u003c\/h3\u003e\n\u003ch3\u003eDisease-Specific Updates:\u003c\/h3\u003e\n\u003cp\u003eChoosing the Right Drug Regimen in IgA Nephropathy (Richard A. Lafayette, MD).\u003c\/p\u003e\n\u003cp\u003eTreating Lupus Nephritis: What’s New in the 2024 KDIGO Guidelines? (Samir V. Parikh, MD).\u003c\/p\u003e\n\u003cp\u003eANCA-Associated Vasculitis: Current Status and Future Perspective (Duvuru Geetha, MD).\u003c\/p\u003e\n\u003ch3\u003ePathophysiology \u0026amp; Diagnostics:\u003c\/h3\u003e\n\u003cp\u003eTargeting the Complement Pathway in Glomerular Disease (Joshua M. Thurman, MD).\u003c\/p\u003e\n\u003cp\u003eHow Genetic Testing Informs Diagnosis and Therapy in 2025 (Benjamin Wooden, MD).\u003c\/p\u003e\n\u003cp\u003eMonoclonal Gammopathy of Renal Significance (MGRS) (Nelson Leung, MD).\u003c\/p\u003e\n\u003ch3\u003eEmerging Concepts:\u003c\/h3\u003e\n\u003cp\u003eExploring the Impact of AI on Glomerular Diseases (Laura H. Mariani, MD).\u003c\/p\u003e\n\u003cp\u003eAntibody Discovery and Podocytopathy Classification (Kristin Meliambro, MD).\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405800263876,"sku":null,"price":130.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-of-Nephrology-Kidney-Week-Glomerular-Diseases-Update-2025.jpg?v=1784216349","url":"https:\/\/medicalcoursespro.com\/products\/american-society-of-nephrology-kidney-week-glomerular-diseases-update-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}